Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns
- 797 Downloads
Several studies support the use of probiotics for the treatment of minor gastrointestinal problems in infants. Positive effects on newborn colics have been evidenced after administration of Lactobacillus strains, whereas no studies have been reported regarding the use of bifidobacteria for this purpose. This work was therefore aimed at the characterization of Bifidobacterium strains capable of inhibiting the growth of pathogens typical of the infant gastrointestinal tract and of coliforms isolated from colic newborns. Among the 46 Bifidobacterium strains considered, 16 showed high antimicrobial activity against potential pathogens; these strains were further characterized from a taxonomic point of view, for the presence and transferability of antibiotic resistances, for citotoxic effects and adhesion to nontumorigenic gut epithelium cell lines. Moreover, their ability to stimulate gut health by increasing the metabolic activity and the immune response of epithelial cells was also studied. The examination of all these features allowed to identify three Bifidobacterium breve strains and a Bifidobacterium longum subsp. longum strain as potential probiotics for the treatments of enteric disorders in newborns such as infantile colics. A validation clinical trial involving the selected strains is being planned.
KeywordsBifidobacterium Probiotics Newborns Enteric disorders Nontumorigenic cell lines
The study was funded by the University of Bologna, Program RFO number J61J10000790001, assigned to Prof. Bruno Biavati. The authors are grateful to Dr. Giovanni Mogna and Dr. Paolo Strozzi of Probiotical SpA for fruitful discussions.
- Benzecri JP (1992) Correspondence analyses handbook. CRC Press, Boca RatonGoogle Scholar
- Biavati B, Mattarelli P (2006) The Family Bifidobacteriaceae prokaryotes: a handbook on the biology of bacteria, 3rd ed, vol 3. Springer, New York, pp 322–382Google Scholar
- EFSA (2005) Opinion of the scientific committee on a request from EFSA related to a generic approach to the safety assessment by EFSA of microorganisms used in food/feed and the production of food/feed additives. EFSA J 226:1–12Google Scholar
- EFSA (2008) Opinion of the Scientific Panel on Additives and Products or Substances used in Animal Feed on the updating of the criteria used in the assessment of bacteria for resistance to antibiotics of human or veterinary importance. EFSA Journal 223:1–12Google Scholar
- Matsuki T, Watanabe K, Tanaka R, Fukuda M, Oyaizu H (1999) Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers. Appl Environ Microbiol 65:4506–4512Google Scholar
- Pipenbaher N, Moeller PL, Dolinšek J, Jakobsen M, Weingartl H, Cencic A (2009) Nitric oxide (NO) production in mammalian nontumorigenic epithelia cells of the small intestine and macrophages induced by individual strains of lactobacilli and bifidobacteria. Int Dairy J 19:166–171CrossRefGoogle Scholar
- Roessler A, Friedrich U, Vogelsang H, Bauer A, Kaatz M, Hipler UC, Schmidt I, Jahreis G (2008) The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin Exp Allergy 38:93–102Google Scholar
- Rowland IR (2008) Prebiotics in human medicine. In: Versalovic J, Wilson M (eds) Therapeutic microbiology: probiotics and related strategies. American Society for Microbiology, Washington DC, pp 299–306Google Scholar
- SAS STAT (1988) User’s guide. Release 6.03 edition. SAS Institute, CaryGoogle Scholar
- Ventura M, Turroni F, Ribbera A, Foroni E, Van Sideren D (2008) Bifidobacteria: the model human gut commensal. In: Versalovic J, Wilson M (eds) Therapeutic microbiology: probiotics and related strategies. American Society for Microbiology, Washington, DC, pp 35–50Google Scholar